Intelligence Feed event · Equity · 2026-10-01

    Survodutide achieves 13.1% weight loss in Phase III trial for obesity and diabetes

    Question

    Survodutide achieves 13.1% weight loss in Phase III trial for obesity and diabetes

    Direct answer

    Phase III clinical readout data from the SYNCHRONIZE-2 study demonstrated that survodutide achieved up to 13.1% body weight reduction in patients with obesity and type 2 diabetes over a 76-week treatment course, substantially outperforming the 3.1% placebo group. The dual agonist mechanism targeting both glucagon and GLP-1 receptors also yielded statistically significant improvements in blood sugar metrics, providing clinical differentiation within the competitive metabolic therapy sector.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-01
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Survodutide achieves 13.1% weight loss in Phase III trial for obesity and diabetes”, revision 1, evidence through 2026-10-01. https://marketontology.com/market-events/2026-10-01/survodutide-achieves-13-1-weight-loss-in-phase-iii-trial-for-obesity-and-diabete-6da263

    EQUITY
    Survodutide achieves 13.1% weight loss in Phase III trial for obesity and diabetes
    Phase III clinical readout data from the SYNCHRONIZE-2 study demonstrated that survodutide achieved up to 13.1% body weight reduction in patients with obesity and type 2 diabetes over a 76-week treatment course, substantially outperforming the 3.1% placebo group. The dual agonist mechanism targeting both glucagon and GLP-1 receptors also yielded statistically significant improvements in blood sugar metrics, providing clinical differentiation within the competitive metabolic therapy sector.
    ZLDPY
    Impact
    76
    OCT 1
    SIG
    92%
    ZLDPY
    Survodutide achieves 13.1% weight loss in Phase III trial for obesity and diabetes
    Phase III clinical readout data from the SYNCHRONIZE-2 study demonstrated that survodutide achieved up to 13.1% body weight reduction in patients with obesity and type 2 diabetes over a 76-week treatment course, substantially outperforming the 3.1% placebo group. The dual agonist mechanism targeting both glucagon and GLP-1 receptors also yielded statistically significant improvements in blood sugar metrics, providing clinical differentiation within the competitive metabolic therapy sector.
    → Positive Phase III obesity efficacy data de-risks regulatory approval and unlocks milestone payments for partner Zealand Pharma.
    Impact
    Phase III clinical readout data from the SYNCHRONIZE-2 study demonstrated that survodutide achieved up to 13.1% body weight reduction in patients with obesity and type 2 diabetes over a 76-week treatment course, substantially outperforming the 3.1% placebo group. The dual agonist mechanism targeting both glucagon and GLP-1 receptors also yielded statistically significant improvements in blood sugar metrics, providing clinical differentiation within the competitive metabolic therapy sector.
    Affected
    ZLDPY
    Transmission
    Positive Phase III obesity efficacy data de-risks regulatory approval and unlocks milestone payments for partner Zealand Pharma.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    ZLDPYcommercialization royalty stream valuation and milestone payments on Phase III clinical successUp1-4wZealand Pharma co-developed survodutide with Boehringer Ingelheim.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month